All In Biotech

Drug Trial Radar · NCT04033367

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Aug 22, 2019

Primary completion

Oct 6, 2021

Study completion Oct 6, 2021

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jul 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD). Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation. To continue to assess the safety and tolerability throughout the study.

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • PlaceboDrug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12Time frame: Baseline, Week 12

Locations

42 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site Number :8400012

    North Little Rock, Arkansas

  • Investigational Site Number :8400002

    Redwood City, California

  • Investigational Site Number :8400001

    Rolling Hills Estates, California

  • Investigational Site Number :8400013

    Colorado Springs, Colorado

  • Investigational Site Number :8400005

    Denver, Colorado

  • Investigational Site Number :8400003

    Sarasota, Florida

  • Investigational Site Number :8400007

    Medford, Oregon

  • Investigational Site Number :8400008

    Charleston, South Carolina

  • Investigational Site Number :0360006

    Phillip, Australian Capital Territory, Australia

  • Investigational Site Number :0360001

    Kogarah, New South Wales, Australia

  • Investigational Site Number :0360007

    Woolloongabba, Queensland, Australia

  • Investigational Site Number :0360003

    Carlton, Victoria, Australia

  • Investigational Site Number :2500001

    Brest, France

  • Investigational Site Number :2500003

    Nantes, France

  • Investigational Site Number :2500002

    Paris, France

  • Investigational Site Number :2500006

    Toulouse, France

  • Investigational Site Number :2760005

    Bad Bentheim, Germany

  • Investigational Site Number :2760002

    Frankfurt am Main, Germany

  • Investigational Site Number :2760006

    Friedrichshafen, Germany

  • Investigational Site Number :2760001

    Göttingen, Germany

  • Investigational Site Number :2760004

    Münster, Germany

  • Investigational Site Number :3760005

    Afula, Israel

  • Investigational Site Number :3760003

    Jerusalem, Israel

  • Investigational Site Number :3800006

    Perugia, Italy

  • Investigational Site Number :3800001

    Pisa, Italy

  • Investigational Site Number :3800004

    Reggio Calabria, Italy

  • Investigational Site Number :3800002

    Roma, Italy

  • Investigational Site Number :3800003

    Siena, Italy

  • Investigational Site Number :3800005

    Rozzano, Milano, Italy

  • Investigational Site Number :7240006

    Córdoba, Spain

  • Investigational Site Number :7240008

    Madrid, Spain

  • Investigational Site Number :7240010

    Madrid, Spain

  • Investigational Site Number :7240005

    Seville, Spain

  • Investigational Site Number :7240002

    Valencia, Spain

  • Investigational Site Number :7240004

    Granada, Andalusia, Spain

  • Investigational Site Number :7240001

    Barcelona / Sabadell, Castille and León, Spain

  • Investigational Site Number :7240003

    Manises, Valencia, Spain

  • Investigational Site Number :7560001

    Bern, Switzerland

  • Investigational Site Number :7840002

    Abu Dhabi, United Arab Emirates

  • Investigational Site Number :7840001

    Dubai, United Arab Emirates

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.